MUC1 and colorectal carcinoma: An analogous study investigated the use of NIRF label IL-783 conjugated to a N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer based nanovector, actively targeted against the early CRC marker under-glycosylated mucin-1 antigen (uMUC-1) using the synthetic peptide EPPT1.